Christopher Mutz - 24 Mar 2022 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Reporting relationship: HEAD OF RARE DISEASE
Issuer ticker: ANIP
Reported as of: 24 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Mar 2022, 20:51:30 UTC
Prior SEC filing: 17 Feb 2022
Next SEC filing: 29 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Christopher Mutz

Key filing fact

Christopher Mutz filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 28 Mar 2022.

Key facts

This page summarizes Christopher Mutz's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Mar 2022, 20:51.

Change

Previous filing in this sequence was filed on 17 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANIP transaction

Common Stock

Award

Transaction value: $0
Shares: +19,428
Change %: +130%
Price: $0.000000
Shares after: 34,378
Date: 24 Mar 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of March 7, 2022.